ADVENZYMESBiotechnology
Advanced Enzyme Technologies Ltd — Cash Flow Statement
₹265.90
-3.13%
Advanced Enzyme Technologies Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 107.72 Cr | 94.06 Cr | 102.18 Cr | 94.11 Cr | — |
| Repayment Of Debt | -5.81 Cr | -0.65 Cr | -0.32 Cr | -2.32 Cr | — |
| Issuance Of Debt | 2.23 Cr | 12.70 Cr | 2.62 Cr | 0.67 Cr | — |
| Issuance Of Capital Stock | 0.38 Cr | 0.00 | 0.14 Cr | 0.43 Cr | — |
| Capital Expenditure | -34.78 Cr | -47.31 Cr | -38.18 Cr | -28.18 Cr | — |
| End Cash Position | 94.22 Cr | 113.75 Cr | 96.42 Cr | 267.36 Cr | — |
| Beginning Cash Position | 113.75 Cr | 96.42 Cr | 267.36 Cr | 191.92 Cr | — |
| Effect Of Exchange Rate Changes | -0.38 Cr | -0.15 Cr | 12.66 Cr | 5.43 Cr | — |
| Changes In Cash | -19.15 Cr | 17.48 Cr | -183.62 Cr | 70.00 Cr | — |
| Financing Cash Flow | -72.54 Cr | -59.24 Cr | -25.80 Cr | -48.50 Cr | — |
| Interest Paid Cff | -3.34 Cr | -2.92 Cr | -2.42 Cr | -1.78 Cr | — |
| Cash Dividends Paid | -59.03 Cr | -56.71 Cr | -12.54 Cr | -11.86 Cr | — |
| Net Common Stock Issuance | 0.38 Cr | 0.00 | 0.14 Cr | 0.43 Cr | — |
| Common Stock Issuance | 0.38 Cr | 0.00 | 0.14 Cr | 0.43 Cr | — |
| Net Issuance Payments Of Debt | -3.58 Cr | 12.05 Cr | 2.30 Cr | -8.14 Cr | — |
| Net Short Term Debt Issuance | -5.81 Cr | 12.70 Cr | 2.62 Cr | -6.49 Cr | — |
| Short Term Debt Payments | -5.81 Cr | — | — | -6.49 Cr | -11.15 Cr |
| Net Long Term Debt Issuance | 2.23 Cr | -0.65 Cr | -0.32 Cr | -1.65 Cr | — |
| Long Term Debt Issuance | 2.23 Cr | — | 0.00 | 0.67 Cr | 8.02 Cr |
| Investing Cash Flow | -89.10 Cr | -64.65 Cr | -298.18 Cr | -3.79 Cr | — |
| Interest Received Cfi | 9.94 Cr | 12.94 Cr | 7.87 Cr | 1.23 Cr | — |
| Net Investment Purchase And Sale | -64.79 Cr | -30.43 Cr | -268.17 Cr | 21.86 Cr | — |
| Purchase Of Investment | -64.79 Cr | -30.43 Cr | -268.17 Cr | -0.24 Cr | — |
| Net Intangibles Purchase And Sale | -0.97 Cr | -0.05 Cr | -0.08 Cr | -0.06 Cr | — |
| Purchase Of Intangibles | -0.97 Cr | -0.05 Cr | -0.08 Cr | -0.06 Cr | — |
| Net PPE Purchase And Sale | -33.28 Cr | -42.16 Cr | -37.85 Cr | -26.82 Cr | — |
| Sale Of PPE | 0.53 Cr | 0.15 Cr | 0.25 Cr | 1.30 Cr | — |
| Purchase Of PPE | -33.81 Cr | -42.31 Cr | -38.10 Cr | -28.12 Cr | — |
| Capital Expenditure Reported | 0.00 | -4.95 Cr | 0.00 | — | — |
| Operating Cash Flow | 142.50 Cr | 141.37 Cr | 140.36 Cr | 122.29 Cr | — |
| Taxes Refund Paid | -59.67 Cr | -49.23 Cr | -36.64 Cr | -54.53 Cr | — |
| Change In Working Capital | -12.23 Cr | -26.25 Cr | -0.34 Cr | -27.40 Cr | — |
| Change In Other Current Liabilities | -2.28 Cr | -0.13 Cr | 2.29 Cr | -2.83 Cr | — |
| Change In Other Current Assets | 13.37 Cr | -3.14 Cr | 1.55 Cr | 0.67 Cr | — |
| Change In Payable | 1.21 Cr | -3.94 Cr | 6.03 Cr | 2.80 Cr | — |
| Change In Inventory | -7.80 Cr | -23.83 Cr | 0.76 Cr | -26.09 Cr | — |
| Change In Receivables | -17.77 Cr | 0.77 Cr | -10.13 Cr | -1.40 Cr | — |
| Other Non Cash Items | -6.08 Cr | 4.98 Cr | -2.11 Cr | 0.72 Cr | — |
| Stock Based Compensation | 3.45 Cr | 3.03 Cr | 0.00 | 0.00 | — |
| Provisionand Write Offof Assets | 1.00 Cr | -4.56 Cr | 0.42 Cr | -0.99 Cr | — |
| Depreciation And Amortization | 36.56 Cr | 35.24 Cr | 35.03 Cr | 34.98 Cr | — |
| Amortization Cash Flow | 7.56 Cr | 7.74 Cr | 7.30 Cr | 8.00 Cr | — |
| Depreciation | 29.00 Cr | 27.50 Cr | 27.73 Cr | 26.98 Cr | — |
| Gain Loss On Investment Securities | -8.22 Cr | -10.85 Cr | 2.20 Cr | -0.33 Cr | — |
| Net Foreign Currency Exchange Gain Loss | -0.08 Cr | -0.08 Cr | -0.11 Cr | -80000.00 | — |
| Gain Loss On Sale Of PPE | -0.22 Cr | 0.23 Cr | 0.80 Cr | -1.15 Cr | — |
| Net Income From Continuing Operations | 187.36 Cr | 187.82 Cr | 140.39 Cr | 171.06 Cr | — |
| Net Other Financing Charges | — | -5.61 Cr | -6.80 Cr | -21.13 Cr | 3.98 Cr |
| Common Stock Dividend Paid | — | -56.71 Cr | -12.54 Cr | -11.86 Cr | -7.98 Cr |
| Short Term Debt Issuance | — | 12.70 Cr | 2.62 Cr | 0.00 | 3.98 Cr |
| Long Term Debt Payments | — | -0.65 Cr | -0.32 Cr | -2.32 Cr | -12.54 Cr |
| Other Cash Adjustment Outside Changein Cash | — | — | 0.02 Cr | — | 0.60 Cr |
| Net Other Investing Changes | — | — | 0.05 Cr | — | — |
| Sale Of Investment | — | — | 0.00 | 22.10 Cr | — |
| Net Business Purchase And Sale | — | — | — | 0.00 | -1.63 Cr |
| Purchase Of Business | — | — | — | 0.00 | -1.63 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Advanced Enzyme Technologies Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.